Changzheng Li

机构：Guangzhou Medical University · ORCID：0000-0002-6226-5843

发表论文 111 篇 · 总被引 2281 次 · h-index 27

代表论文

• Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial (2023 · The Lancet Oncology · 被引 206)
• Amino acid catabolism regulates hematopoietic stem cell proteostasis via a GCN2-eIF2α axis (2022 · Cell stem cell · 被引 93)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial (2024 · Nature Medicine · 被引 45)
• Apoptotic vesicles are required to repair DNA damage and suppress premature cellular senescence (2024 · Journal of Extracellular Vesicles · 被引 39)
• Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness (2022 · Blood · 被引 38)